Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer

opdivo
BMS' Opdivo is looking to expand its reach in bladder cancer. (Bristol Myers Squibb)

Bristol Myers Squibb’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The company revealed Thursday that its PD-1 fighter, against placebo, had lengthened the time muscle-invasive urothelial carcinoma patients could remain disease-free after surgery. All patients saw benefit, regardless of whether their tumors expressed levels of biomarker PD-L1.

RELATED: Roche's Tecentriq flops in post-surgery muscle-invasive bladder cancer

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

The results mark the first time a member of the PD-1/L1 class has cut patients’ risk of relapse in the adjuvant setting—and they “point to the potential for (Opdivo) to become a new standard of care,” Matthew Galsky, M.D., professor and co-director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, said in a statement.

BMS is glad to have that distinction. Currently, Opdivo is cleared only in metastatic bladder cancer, where Merck’s Keytruda, AstraZeneca’s Imfinzi, Roche’s Tecentriq and Pfizer and Merck KGaA’s Bavencio also bear green lights.

It’s not for lack of trying, though. Earlier this year, Roche revealed that Tecentriq had flopped a trial in the same setting as Opdivo’s latest win, failing to show a benefit compared with placebo at delaying the time to cancer recurrence or death.

RELATED: ESMO: Bristol Myers' Opdivo racks up GI cancer data for 2 potentially practice-changing FDA nods

Meanwhile, the victory comes on the heels of the European Society for Medical Oncology’s virtual annual meeting, where Opdivo racked up an adjuvant success in esophageal cancer. With immuno-oncology drugmakers working to move their medicines—initially approved only in the metastatic setting—earlier into treatment, Bristol’s drug has now posted positive adjuvant trials in those two disease areas plus melanoma.

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.